Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.

被引：0
|
作者：
Irwin, Debra E.
Thompson, Stephen
Ribalov, Rinat
Choudhry, Azhar
机构：
[1] IBM Watson Hlth, Cambridge, MA USA
[2] Teva Pharmaceut Inc, Parsippany, NJ USA
[3] Teva Pharmaceut Ind LTD, Petah Tiqwa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19503
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    Fraser, G.
    Cramer, P.
    Demirkan, F.
    Silva, R. Santucci
    Grosicki, S.
    Pristupa, A.
    Janssens, A.
    Mayer, J.
    Bartlett, N. L.
    Dilhuydy, M-S
    Pylypenko, H.
    Loscertales, J.
    Avigdor, A.
    Rule, S.
    Villa, D.
    Samoilova, O.
    Panagiotidis, P.
    Goy, A.
    Pavlovsky, M. A.
    Karlsson, C.
    Hallek, M.
    Mahler, M.
    Salman, M.
    Sun, S.
    Phelps, C.
    Balasubramanian, S.
    Howes, A.
    Chanan-Khan, A.
    LEUKEMIA, 2019, 33 (04) : 969 - 980
  • [42] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
  • [43] Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With First-Line Idelalisib Plus Rituximab After Cessation of Treatment for Toxicity
    Thompson, Philip A.
    Stingo, Francesco
    Keating, Michael J.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Wierda, William G.
    Kadia, Tapan M.
    O'Brien, Susan M.
    CANCER, 2016, 122 (16) : 2505 - 2511
  • [44] Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
    Huntington, Scott F.
    Soulos, Pamela R.
    Barr, Paul M.
    Jacobs, Ryan
    Lansigan, Frederick
    Odejide, Oreofe O.
    Schwartzberg, Lee S.
    Davidoff, Amy J.
    Gross, Cary P.
    BLOOD, 2019, 134
  • [45] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    G. Fraser
    P. Cramer
    F. Demirkan
    R. Santucci Silva
    S. Grosicki
    A. Pristupa
    A. Janssens
    J. Mayer
    N. L. Bartlett
    M.-S. Dilhuydy
    H. Pylypenko
    J. Loscertales
    A. Avigdor
    S. Rule
    D. Villa
    O. Samoilova
    P. Panagiotidis
    A. Goy
    M. A. Pavlovsky
    C. Karlsson
    M. Hallek
    M. Mahler
    M. Salman
    S. Sun
    C. Phelps
    S. Balasubramanian
    A. Howes
    A. Chanan-Khan
    Leukemia, 2019, 33 : 969 - 980
  • [46] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial
    Fraser, Graeme
    Chanan-Khan, Asher
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Bartlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Masha
    Howes, Angela
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 : 98 - 100
  • [47] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [48] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [49] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [50] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
12345